Citations

Clear

554 citation(s) found for "Li, Gerald".

Mild Renal Insufficiency Results in Increases in Myocardial Collagen: Evidence for a Heart – Kidney Connection
Martín, Fernando L., Huntley, Brenda K., Harders, Gerald E., Chen, Horng H. , Burnett, John C. , Cataliotti, Alessandro

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.761.14 Get It

Decreased renal function is associated with increased CV morbidity and mortality. The changes mild renal impairment may cause structurally/molecularly in the heart remain unclear. We hypothesized that mild renal dysfunction produced by unilateral nephrectomy(UNX)results in changes in ventricular structure and gene expression in the absence of hypertension or vol overload. Wistar rats were used[sham (S; n=10) and UNX; n=9]. At 4 weeks, GFR was determined by inulin clearance and RBF by PAH. Hearts and kidneys were harvested for histological analysis. Cardiac function assessed by echo. Genomewide microarray analysis was performed on LV myocardium (Affymetrix). Glomerular hypertrophy was observed in UNX. GFR tended to decrease with a reduction in RBF (S:8±1, Nx:5±1 ml/min, p<0.005). Blood pressure (BP), Na and water excretions were maintained without activation of PRA, aldo or BNP. LVEF and LV diameters were normal. Microarray analysis of LV revealed that 278 genes changed with UNX (1.5 fold, P<0.05) related to cell growth, bone remodeling and muscle contraction (Z value>2). Importantly, Pic Red staining in the LV of UNX revealed greater fibrosis (S:2±0.1, Nx:4±0.4 %, p<0.001). We conclude that mild renal insufficiency initiates myocardial gene responses and fibrosis independent of alterations in the circulating RAAS, BNP, BP, vol overload or systolic dysfunction.
Heart – Kidney Connection: Myocardial Infarction Induces Widespread Changes in Renal Cortical and Medullary Gene Expression together with Cortical and Medullary Fibrosis
Martín, Fernando L., Huntley, Brenda K., Harders, Gerald E., Sandberg, Sharon M., Heublein, Denise M., Burnett, John C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.970.34 Get It

Studies in human myocardial infarction (MI) suggest that even in the absence of heart failure (HF) alterations in renal function may occur and contribute to poor outcomes. We hypothesized that even without preexisting renal disease, renal functional, structural and molecular changes would be present following MI. Wistar rats were used, Sham(S;n=10) and MI(n=9). 3 weeks after MI, GFR was determined by inulin clearance. Blood was obtained for PRA and aldosterone. Cardiac function was assessed by echo. Genomewide microarray analysis was performed on kidney cortex (KC) and medulla (KM) (Affymetrix). EF decreased after MI (S:63±2, MI:43±6%, p<0.01) and LVEDd increased. PRA, aldosterone and blood pressure (BP) did not change. There was no HF as Na and water excretion was maintained. GFR tended to decrease. Pic Red staining in the KC and KM after MI showed greater fibrosis (KC S:1±0.2, MI:3±0.6%, p<0.001 and KM S:1±0.2, MI:19±6%, p<0.005). Microarray analysis showed that 303 genes changed in KM and 407 genes in KC after MI (1.5 fold, P<0.05) related to structure morphogenesis and metabolic processes(Z value>2). We conclude that experimental MI results in renal structural remodeling characterized by cortical and medullary fibrosis with a mild reduction in GFR and extensive modulation of molecular pathways related to renal growth and morphogenesis underscoring a heart‐kidney connection after MI.
Evidence of functional NBCe1 (SLC4A4) dimer assembly
Chang, Min‐Hwang , Babcock, Ǵerald, Romero, Michael F.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 21 | Issue: 6 | Pages: No page available

10.1096/fasebj.21.6.a1282-c Get It

Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE
Kim, Sunghee , Pieper, Karen S. , Ezekowitz, Michael D. , Ansell, Jack , Berger, Peter B. , Reiffel, James A. , Singer, Daniel E. , Kowey, Peter R. , Piccini, Jonathan P. , O’Brien, Emily C. , Kaufman, Brystana G. , Fonarow, Gregg C. , Naccarelli, Gerald V. , Mahaffey, Kenneth W. , Chan, Paul S. , Allen, Larry A. , Freeman, James V. , Gersh, Bernard J. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 21, 2021 | Volume: 10 | Issue: suppl_3 | Pages: No page available

10.1161/circoutcomes.10.suppl_3.057 Get It

Introduction: Patient understanding of available therapies for atrial fibrillation (AF) is foundational to shared medical decision making and long term medication adherence. Yet, there is a paucity of data regarding the extent to which patients newly diagnosed with AF in routine community practice understand their options. Hypotheses: 1) Understanding of warfarin, novel oral anticoagulants (NOAC), rhythm control therapy, cardioversion and radio frequency ablation changes little from baseline to 6 months and 2) treatment rates at 6 months are associated with patient understanding of therapies at baseline. Methods: We analyzed survey data from SATELLITE, a substudy of new-onset AF patients enrolled at 56 US sites participating in the ORBIT-AF registry. Patients were surveyed at the baseline and 6 month follow up clinic visit using Likert scales. Agreement between time points was assessed with the McNemar test, and the relationship between understanding and treatment was assessed only for the subset not on treatment at baseline. Results: Of 1000 patients enrolled in SATELLITE, 506 had 6-month survey data (data collection is continuing). Among these, the median age was 69.0 years (IQR 63.0 - 76.0) and 93.7% (474 of 506) were white. There was evidence of improvement in the self-reported understanding of warfarin and NOACs from baseline to 6 months, but not for rhythm control, ablation or cardioversion. The proportion reporting high understanding improved significantly for warfarin (p<.0001) and NOACs (p<.0001) from 47% (223 of 474) and 51% (245 of 481) at baseline to 60% (284 of 474) and 69% (332 of 481) at 6 months respectively (Figure 1). Patients with high understanding of the benefits of ablation (p=0.0005) and options for ablation (p=0.0093) at baseline were more likely to have this therapy at the 6 month follow up (N=590), but improved understanding was not associated with increased use of warfarin/NOACs (N=83) or rhythm control (N=444). Conclusions: Patients with new-onset AF had improved self-reported understanding of some treatment options over the first 6-months from diagnosis; however, factors other than patient understanding may influence AF treatments received at 6 months. Patient understanding of AF treatments remains suboptimal at 6 months, and our results suggest a need for ongoing patient education.
Cardiorenal Connection: Uninephrectomy Results in Cardiac Gene Changes Despite Normal Cardiac Function
Martín, Fernando L., Huntley, Brenda K., Harders, Gerald E., Gilman, Gregory, Burnett, John C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 21 | Issue: 6 | Pages: No page available

10.1096/fasebj.21.6.a1409-c Get It

Decreased renal function is associated with increased CV morbidity and mortality. However, the impact of mild renal dysfunction upon the heart remains to be fully elucidated. It is thought that a mild reduction in renal mass is not deleterious to the heart, yet exploration of the impact of unilateral nephrectomy (Nx) on myocardial gene responses is undefined. We hypothesized that even when ventricular function and structure are grossly preserved after Nx, such a reduction in renal mass and function would result in significant alterations in the cardiac genome. Wistar rats, Sham(S)(n=10), Nx(n=9). 4 weeks after Nx we assessed proteinuria, UNaV, UcGMP and BNP. Cardiac function was assessed by echo. GFR was determined by inulin clearance and renal blood flow (RBF) by PAH. Blood was obtained for BNP, aldosterone and cGMP. Kidneys and hearts were harvested. Gene microarrays were conducted of left ventricle (LV) myocardium (Affymetrix GeneChip® Rat Genome 230 2.0). GFR strongly tended to decrease and RBF was decreased in Nx (S:8±1, Nx:5±1 ml/min, p<0.005). Glomerular volume was increased in Nx (S:1±0.04, Nx:1.6±0.1 u 3 ×10 6 , p<0.001) while UNaV and volume were not different. There was no proteinuria in Nx. EF, LV end systolic and diastolic diameters were normal. Blood pressure (BP) was unchanged. There was no activation of the systemic RAAS or BNP. Importantly, 278 cardiac genes changed their expression after Nx (1.5 fold, P<0.05). 11% were increased and 89% decreased. Pathways involved included cell adhesion, growth and proliferation. We conclude that Nx, independently of alterations in circulating RAAS or BNP, BP or myocardial structure and function, results in widespread changes in myocardial gene expression. Further long‐term studies are needed to define the impact of these early gene responses to myocardial structure and function.
Multiple roles of ErbB4, an epidermal growth factor receptor, in zebrafish embryonic development.
Babcock, Ǵerald, Sussman, Caroline R. , Plata, Consuelo , Liang, Jennifer O.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 21 | Issue: 6 | Pages: No page available

10.1096/fasebj.21.6.a1426-c Get It

Members of the epidermal growth factor family and its receptors (EGFR/ErbBs 1–4) critically regulate the development and maintenance of numerous tissues including CNS, heart, kidney, GI tract, and muscle, accounting for a variety of congenital malformations, tumor growth, renal cyst formation, and heart failure. We cloned erbB4 from zebrafish (Danio rerio) and examined its effects on embryonic development by reducing its expression through injection of antisense morpholinos (MO) into zebrafish embryos at the 1–2 cell‐stage. Zebrafish ErbB4 was 73% identical to rat and human ErbB4. In situ hybridization using two non‐overlapping probes both showed expression 10 hours post‐fertilization throughout the embryo with expression resolving to the brain, eye, heart, kidney, and GI tract (intestine, liver, pancreas) over the next 5 days. Injection of two 5′ non‐overlapping MO both demonstrated altered development of multiple organs including brain, eyes, heart, and tail. Effects ranged in severity from complete lack of head, heart, and tail formation to stunted head, eye, and tail formation, distended pericardium, and unfolded heart tube. These studies demonstrate multiple critical roles for ErbB4 in development, and the utility of the zebrafish model system for these studies. AHA30137N, EY017732 , Case Aces/NSF Advance, Wadsworth Foundation.
Fatty liver accompanies an increase of Lactobacillus acidophilus in the hind gut of C57/BL mice fed a high‐fat diet
Combs, Gerald F., Zeng, Huawei , Liu, Jun , Jackson, Matthew Irick , Yan, Lin

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.1067.4 Get It

High‐fat diets induce changes in the gut microbiome and induce nonalcoholic fatty liver disease. This study tested the hypothesis that high‐fat feeding increases certain predominant hind gut bacteria in a C57BL/6 mouse model of obesity. We found that a high‐fat diet produced significant increases in both body weight and body fat percentage in C57BL/6 mice compared with a control group fed a low‐fat diet. With an immunohistochemical approach, we found that these changes were associated with increases in lipid droplets, inflammatory cell infiltration and inducible nitric oxide synthase (iNOS) level in the livers of mice fed the high‐fat diet. In addition, plasma leptin and tumor necrosis factor (TNFα) levels were elevated in mice fed the high‐fat diet, indicative of chronic inflammation. Eight out of twelve bacterial species that typically predominate hind gut microbial ecology were detected in fecal samples by DNA analysis. The DNA amount of one of these species, Lactobacillus (L.) acidophilus , was 6900‐fold greater in high‐fat fed mice compared to controls. L. acidophilus can promote inflammatory production of cytokines such as TNFα, which was also elevated in high‐fat fed mice. These results suggest that changes in the hindgut microbiome which accompany high fat feeding may contribute to the development of steatohepatitis in obese mice.
Extradural decompression versus duraplasty in Chiari malformation type I with syrinx: outcomes on scoliosis from the Park-Reeves Syringomyelia Research Consortium
Sadler, Brooke , Skidmore, Alex, Gewirtz, Jordan I. , Anderson, Richard C. E. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Averill, Christine, Baird, Lissa , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Bonfield, Christopher M. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Jea, Andrew, Keating, Robert F., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , Mapstone, Timothy B., McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., Oakes, W. Jerry, Olavarria, Greg, O’Neill, Brent R., Ragheb, John , Shannon, Chevis N. , Smith, Jodi L. , Stone, Scellig , Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Park, Tae Sung, Limbrick, David D. , Strahle, Jennifer M. , Skidmore, Alexander, Haller, Gabe , Ahmed, Raheel , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Johnston, James M. , Khan, Nickalus R. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 18, 2021 | Volume: 28 | Issue: 2 | Pages: 167-175

10.3171/2020.12.peds20552 | PMID 34144521 Get It

OBJECTIVE Scoliosis is common in patients with Chiari malformation type I (CM-I)–associated syringomyelia. While it is known that treatment with posterior fossa decompression (PFD) may reduce the progression of scoliosis, it is unknown if decompression with duraplasty is superior to extradural decompression. METHODS A large multicenter retrospective and prospective registry of 1257 pediatric patients with CM-I (tonsils ≥ 5 mm below the foramen magnum) and syrinx (≥ 3 mm in axial width) was reviewed for patients with scoliosis who underwent PFD with or without duraplasty. RESULTS In total, 422 patients who underwent PFD had a clinical diagnosis of scoliosis. Of these patients, 346 underwent duraplasty, 51 received extradural decompression alone, and 25 were excluded because no data were available on the type of PFD. The mean clinical follow-up was 2.6 years. Overall, there was no difference in subsequent occurrence of fusion or proportion of patients with curve progression between those with and those without a duraplasty. However, after controlling for age, sex, preoperative curve magnitude, syrinx length, syrinx width, and holocord syrinx, extradural decompression was associated with curve progression > 10°, but not increased occurrence of fusion. Older age at PFD and larger preoperative curve magnitude were independently associated with subsequent occurrence of fusion. Greater syrinx reduction after PFD of either type was associated with decreased occurrence of fusion. CONCLUSIONS In patients with CM-I, syrinx, and scoliosis undergoing PFD, there was no difference in subsequent occurrence of surgical correction of scoliosis between those receiving a duraplasty and those with an extradural decompression. However, after controlling for preoperative factors including age, syrinx characteristics, and curve magnitude, patients treated with duraplasty were less likely to have curve progression than patients treated with extradural decompression. Further study is needed to evaluate the role of duraplasty in curve stabilization after PFD.
Successful encorafenib desensitization in a patient with recurrent metastatic melanoma
Cullen, Grace , Finnes, Heidi D. , Volcheck, Gerald W., Cullen, Grace D , Markovic, Svetomir N.

Mayo Clinic

Melanoma Research | June 16, 2021 | Volume: 31 | Issue: 4 | Pages: 402-404

10.1097/cmr.0000000000000757 | PMID 34193805 Get It

Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda, Elena , Sukari, Ammar , Patnaik, Amita , Lou, Yanyan , Golan, Talia , Geva, Ravit , Miguel, Maria De, Palcza, John, Jha, Sujata , Chaney, Marya , Healy, Jane, Lakhani, Nehal J. , Im, Seock‐Ah , Wermke, Martin , Miguel, Maria De, Falchook, Gerald Steven

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 3584-3584

10.1200/jco.2021.39.15_suppl.3584 Get It

3584 Background: Patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed on ≥2 prior therapies have limited treatment options, with median OS ranging from 6-9 months (mo). In the dose-escalation phase of this first-in-human multicohort study (NCT02720068), the anti-lymphocyte activation gene (LAG)-3 antibody favezelimab (fave) was well tolerated alone and with pembrolizumab (pembro) across all dose levels (Lakhani, SITC, 2018, abstract O26). Here, we evaluate the safety and efficacy of fave alone or in combination with pembro in pts with advanced MSS CRC from the dose confirmation phase. Methods: Eligible pts with MSS PD-1/PD-L1-treatment-naïve mCRC that progressed on prior standard-of-care (3L+) were enrolled (cohort A) to receive the RP2D of 800 mg fave alone (Arm 1), 800 mg fave + 200 mg pembro (Arm 2C), or 800 mg fave + 200 mg pembro (MK-4280A) co-formulation (Arm 5), all Q3W. Treatment continued for 35 cycles or until progression, unacceptable toxicity, or investigator/pt decision. Pts with confirmed progression per irRECIST v1.1 on fave alone could crossover to 800 mg fave + pembro. Safety was assessed in all treated pts; efficacy in the full analysis set (FAS) of all treated pts with baseline scan. Objectives included safety (primary), ORR (RECIST v1.1 by investigator [secondary]), and DOR, PFS, and OS (exploratory). Interim analysis data cut-off was: Oct. 23, 2020. Results: A total of 20 pts received fave (Arm 1); 89 pts (including 9 crossover) received fave + pembro (Arms 2C+5); 12 pts (Arm 1) and 36 pts (Arms 2C+5), had PD-L1 CPS ≥1 tumors. At data cut-off, median follow-up was 5.8 months (mo) in Arm 1 and 6.2 mo in Arms 2C+5. Treatment-related adverse events (TRAEs) were 65% with fave (Arm 1) and 65.2% with fave + pembro (Arms 2C+5). Grade ≥3 TRAEs were 15% (Arm 1), and 20% [Arms 2C+5]). No grade 5 TRAEs were reported. Common TRAEs (≥15%) included fatigue (20.0%), nausea (15%) with fave, and fatigue (16.9%) with fave + pembro. Confirmed ORR was 6.3% (4PR, 1CR) with fave + pembro (Arms 2C+5). No pt receiving fave alone responded. In Arms 2C+5, median DOR was 10.6 mo (range, 5.6-12.7). ORR, OS and PFS by PD-L1 status are reported in the Table. Conclusions: Favezelimab alone or in combination with pembrolizumab had a manageable safety profile, with no treatment-related deaths. Promising antitumor activity was observed with combination therapy, including with MK-4280A, compared with monotherapy most notably in pts with PD-L1 CPS ≥1 tumors. Clinical trial information: NCT02720068. [Table: see text]